OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
20
Results
Show all
Save search
Copy query
Show results for
Unknown
(20)
Publication Date
Release Date
2025
(4)
2021
(4)
2020
(4)
2023
(3)
2022
(3)
2024
(1)
2018
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge.
Not available
S-EPMC7465130
|
biostudies-literature
Cite
Management of Elderly Colorectal Cancer Patients: A Comprehensive Review Encompassing Geriatric Assessment.
Not available
S-EPMC12564925
|
biostudies-literature
Cite
Molecular screening with liquid biopsy for anti-EGFR retreatment in metastatic colorectal cancer: preliminary data from the randomized phase 2 PARERE trial.
Not available
S-EPMC10889120
|
biostudies-literature
Cite
TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable
RAS
and
BRAF
wild-type metastatic colorectal cancer.
Not available
S-EPMC6045747
|
biostudies-literature
Cite
Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
Not available
S-EPMC8551530
|
biostudies-literature
Cite
Upfront Modified Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan Plus Panitumumab Versus Fluorouracil, Leucovorin, and Oxaliplatin Plus Panitumumab for Patients With
RAS/BRAF
Wild-Type Metastatic Colorectal Cancer: The Phase III TRIPLETE Study by GONO.
Not available
S-EPMC9426812
|
biostudies-literature
Cite
Clinical, Pathological and Prognostic Features of Rare BRAF Mutations in Metastatic Colorectal Cancer (mCRC): A Bi-Institutional Retrospective Analysis (REBUS Study).
Not available
S-EPMC8123617
|
biostudies-literature
Cite
Prognostic and predictive impact of consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer: a translational analysis of the TRIBE2 study.
Not available
S-EPMC8103536
|
biostudies-literature
Cite
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
Not available
S-EPMC8018298
|
biostudies-literature
Cite
Prognostic impact and clinical management of pT4N0 colon cancer: data from a large, multicenter, international, real-world dataset.
Not available
S-EPMC12281219
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets